NKTR · Nektar Therapeutics
$73.02
-2.90 (-3.82%)
At close · Aug 14
Market Cap
$2.49B
Shares
34.14M
Nektar Therapeutics Earnings Call Transcripts
Every quarterly earnings call for Nektar Therapeutics (NKTR) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▼5.2%
$23.62M
−$59.05M
'22 Q3
22-11-03
▼11.9%
$22.02M
−$59.69M
'22 Q4
23-01-09
▼13%
$21.59M
−$137.02M
'23 Q1
23-04-17
▼5%
$20.50M
−$51.12M
'23 Q2
23-08-08
▲2.2%
$24.14M
−$45.84M
'23 Q3
23-11-07
▲8.5%
$23.89M
−$42.08M
'23 Q4
24-03-04
▲0.2%
$21.64M
−$36.80M
'24 Q1
24-05-09
▲14.6%
$23.49M
−$52.36M
'24 Q2
24-08-08
▼0.1%
$24.12M
−$37.06M
'24 Q3
24-11-07
▲22.1%
$29.18M
$7.26M
'24 Q4
25-03-12
▼51.7%
$10.46M
−$50.88M
'25 Q1
25-05-08
▼52.4%
$11.18M
−$41.59M
'25 Q2
25-08-07
▼51.1%
$11.79M
−$35.52M
'25 Q3
25-11-06
▼25.3%
$21.81M
−$36.08M
'25 Q4
26-03-12
▲3.8%
$10.86M
−$44.90M
'26 Q1
26-05-07
LATEST
▼9.3%
$10.13M
−$40.62M
'26 Q2
26-08-13
Earnings call
FY26 · Q2
2026-08-13
Nektar Therapeutics Q2 FY2026 Earnings Call
Confident tone
Market research and first-line positioning for ResPeg
Atopic dermatitis dosing durability
Alopecia areata Phase 3 / long-term extension
Revenue
$10.13M
▼ 9.3% YoY Diluted EPS
$-1.23
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-03
2026 Jefferies Global Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-07
Nektar Therapeutics Q1 FY2026 Earnings Call
Confident tone
Atopic dermatitis (ectopic dermatitis) program
Alopecia areata program
Regulatory risk on moderate-population expansion
Revenue
$10.86M
▲ 3.8% YoY Diluted EPS
$-1.82
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-12
Nektar Therapeutics Q4 FY2025 Earnings Call
Confident tone
Rezpeg/Respag in atopic dermatitis
Balance sheet and financing
Phase 3 readiness and regulatory alignment
Revenue
$21.81M*
▼ 25.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-06
Nektar Therapeutics Q3 FY2025 Earnings Call
Confident tone
REZPEG in atopic dermatitis (RESOLVE-AD)
Alopecia areata Phase IIb (RESOLVE-AA)
Type 1 diabetes / TrialNet partnership
Revenue
$11.79M
▼ 51.1% YoY Diluted EPS
$-1.87
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Nektar Therapeutics Q2 FY2025 Earnings Call
Confident tone
REZPEG/rezpegaldesleukin lead program
Atopic dermatitis Phase IIb REZOLVE-AD results
FDA Fast Track and Phase III planning
Revenue
$11.18M
▼ 52.4% YoY Diluted EPS
$-2.95
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Nektar Therapeutics Q1 FY2025 Earnings Call
Positive tone
REZPEG in atopic dermatitis (REZOLVE-AD)
Early-stage pipeline (TNFR2 agonist)
REZPEG in alopecia areata
Revenue
$10.46M
▼ 51.7% YoY Diluted EPS
$-3.62
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-12
Nektar Therapeutics Q4 FY2024 Earnings Call
Revenue
$29.18M*
▲ 22.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Nektar Therapeutics Q3 FY2024 Earnings Call
Confident tone
REZPEG in atopic dermatitis
REZPEG in alopecia areata
NKTR-255 oncology program
Revenue
$24.12M
▼ 0.1% YoY Diluted EPS
$-2.66
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Nektar Therapeutics Q2 FY2024 Earnings Call
Revenue
$23.49M
▲ 14.6% YoY Diluted EPS
$-3.76
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
Nektar Therapeutics Q1 FY2024 Earnings Call
Confident tone
REZPEG in atopic dermatitis
REZPEG in alopecia areata
NKTR-0165 TNFR2 agonist
Revenue
$21.64M
▲ 0.2% YoY Diluted EPS
$-2.85
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-04
Nektar Therapeutics Q4 FY2023 Earnings Call
Confident tone
REZPEG in atopic dermatitis
TNFR2 / NKTR-0165 program
REZPEG in alopecia areata
Revenue
$23.89M*
▲ 8.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-07
Nektar Therapeutics Q3 FY2023 Earnings Call
Revenue
$24.14M
▲ 2.2% YoY Diluted EPS
$-3.60
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
Nektar Therapeutics Q2 FY2023 Earnings Call
Revenue
$20.50M
▼ 5% YoY Diluted EPS
$-4.05
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-04-17
Nektar Therapeutics Q1 FY2023 Earnings Call
Revenue
$21.59M
▼ 13% YoY Diluted EPS
$-10.95
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-01-09
Nektar Therapeutics Q4 FY2022 Earnings Call
Revenue
$22.02M*
▼ 11.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Nektar Therapeutics Q3 FY2022 Earnings Call
Revenue
$23.62M
▼ 5.2% YoY Diluted EPS
$-4.65
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Nektar Therapeutics Q2 FY2022 Earnings Call
Revenue
$21.59M
▼ 23.8% YoY Diluted EPS
$-12.75
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Nektar Therapeutics Q1 FY2022 Earnings Call
Revenue
$24.82M
▲ 5% YoY Diluted EPS
$-7.35
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-01-11
Nektar Therapeutics Q4 FY2021 Earnings Call
Revenue
$25.01M
▲ 6.6% YoY Diluted EPS
$-11850.00
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-04
Nektar Therapeutics Q3 FY2021 Earnings Call
Revenue
$24.92M
▼ 17% YoY Diluted EPS
$-10.50
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-05
Nektar Therapeutics Q2 FY2021 Earnings Call
Revenue
$28.33M
▼ 42% YoY Diluted EPS
$-10.35
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
Nektar Therapeutics Q1 FY2021 Earnings Call
Revenue
$23.65M
▼ 53.2% YoY Diluted EPS
$-10.20
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-01-11
Nektar Therapeutics Q4 FY2020 Earnings Call
Revenue
$23.46M
▼ 30.7% YoY Diluted EPS
$-9.75
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Nektar Therapeutics Q3 FY2020 Earnings Call
Revenue
$30.03M
▲ 2.8% YoY Diluted EPS
$-9.15
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
Nektar Therapeutics Q2 FY2020 Earnings Call
Revenue
$48.85M
▲ 109.5% YoY Diluted EPS
$-6.75
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-07
Nektar Therapeutics Q1 FY2020 Earnings Call
Revenue
$50.57M
▲ 79.2% YoY Diluted EPS
$-11.70
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-01-13
Nektar Therapeutics Q4 FY2019 Earnings Call
Revenue
$33.86M
▼ 15% YoY Diluted EPS
$-9.60
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–28 of 28 earnings calls
Key facts
CIK
906709
CUSIP
640268306
13F (30d)
249 filings
234 filers
Visit website
Investor relations